Programme 2008

2008 NCRI Cancer Conference
Sunday 5 October – Wednesday 8 October
The International Convention Centre, Birmingham

CME Accreditation: This conference has been approved by the Federation of the Royal College of Physicians of the UK for 20 external CPD credits
Programme Contents

Programme at a glance 3

Symposia in detail 9
The Conference features a number of high-quality symposia, each designed to attract a broad spectrum of cancer specialists.

Parallel sessions in detail 11
This year’s sessions cover a breadth of topics, spanning the central themes of: The Cancer Patient; Diagnosis and Therapy; The Cancer Cell; Epidemiology and Prevention; and Information and Delivering Cancer Care.

Workshops in detail 29
The Conference also features a range of workshops designed to provide opportunities for development and networking.
## Programme at a glance Sunday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30 – 14.45</td>
<td>Satellite workshop: metabolism and signalling in cancer</td>
</tr>
<tr>
<td></td>
<td>The Cancer Recognised Research Group in Northern Ireland (CRRG) Workshop</td>
</tr>
<tr>
<td>13.30 – 14.30</td>
<td>Public seminar and open forum: International comparisons and the impact on UK cancer care</td>
</tr>
<tr>
<td></td>
<td>Michel Coleman</td>
</tr>
<tr>
<td></td>
<td>London School of Hygiene and Tropical Medicine, University of London, UK</td>
</tr>
<tr>
<td>14.45 – 15.00</td>
<td>Welcome address</td>
</tr>
<tr>
<td></td>
<td>Sir Kenneth Calman</td>
</tr>
<tr>
<td></td>
<td>NCRI Chairman</td>
</tr>
<tr>
<td>15.00 – 15.40</td>
<td>Chromatin modifying enzymes: their function and role in cancer</td>
</tr>
<tr>
<td></td>
<td>Tony Kouzarides</td>
</tr>
<tr>
<td></td>
<td>Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK</td>
</tr>
<tr>
<td>15.40 – 16.20</td>
<td>Normalising tumour vessels and microenvironment to treat cancer: from the bench to bedside and back</td>
</tr>
<tr>
<td></td>
<td>Rakesh Jain</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital and Harvard Medical School, Boston, USA</td>
</tr>
<tr>
<td>16.20 – 18.10</td>
<td>Poster Session 1 and Refreshment Break</td>
</tr>
<tr>
<td>18.10 – 18.50</td>
<td>Dying with dignity: a contemporary challenge in palliative cancer care</td>
</tr>
<tr>
<td></td>
<td>Harvey Chochinov</td>
</tr>
<tr>
<td></td>
<td>University of Manitoba and Manitoba Palliative Care Research Unit, Canada</td>
</tr>
<tr>
<td>18.50 – 19.30</td>
<td>The causes and prevention of breast cancer</td>
</tr>
<tr>
<td></td>
<td>Valerie Beral</td>
</tr>
<tr>
<td></td>
<td>University of Oxford, UK</td>
</tr>
<tr>
<td>19.30 – 21:00</td>
<td>Opening Reception and Trade Exhibition</td>
</tr>
<tr>
<td>20.00 – 21.30</td>
<td>How does knowledge of genetic and lifestyle factors help us prevent breast cancer?</td>
</tr>
<tr>
<td></td>
<td>Breakthrough/Breast Cancer Campaign Open Discussion</td>
</tr>
</tbody>
</table>
Programme at a glance  

**Monday**

**08.00 – 08.50**  
Educational Workshops  
- BOA Educational Workshop  
- BACR Educational Workshop

**09.00 – 09.10**  
Introduction to the programme  
**Stan Kaye**  
Chair of the Programme Planning Committee

**09.10 – 09.50**  
Controlling the cell cycle  
**Sir Paul Nurse**  
Rockefeller University, New York, USA

**09.50 – 10.30**  
Preinvasive disease: catching it earlier, understanding it better, hitting it harder  
**Rebecca Fitzgerald**  
Hutchison-MRC Research Centre, Cambridge, UK

**10.30 – 11.00**  
Refreshment Break and Exhibition Viewing

**11.00 – 12.30**  
Symposia  
- Living beyond cancer  
  **Hosted by Jessica Corner and Jane Maher**  
  Macmillan Cancer Support, UK  
- Targeting vascular biology  
  **Hosted by Tim Eisen**  
  Hutchison/MRC Research Centre, Cambridge, UK  
- The cell cycle in cancer  
  **Hosted by John Diffley**  
  CR-UK London Research Institute, UK

**12.30 – 15.00**  
Poster Session 2, Trade Exhibition, and Lunch

**13.00 – 14.00**  
Commercial Workshop  
- K-RAS status in colorectal cancer: tailoring treatment to your patient – sponsored by Merck Serono

**14.00 – 15.00**  
Workshops  
- Alternative and innovative designs of Phase I/II trials  
- How to publish and disseminate your results  
- Leadership in scientific research  
- NCRI data-sharing debate
15.15 – 17.30 Parallel sessions
- Colorectal cancer
- Depression and assisted suicide in cancer patients
- Ensuring equality and diversity in trial recruitment
- Genome stability in cancer
- Hormones and cancer
- Mechanisms of resistance
- Melanoma
- Paediatrics
- Understanding health behaviours relevant to cancer
- Proffered Paper Highlights (Session 1)

17.30 – 18.00 Refreshment Break

18.00 – 19.00 Clinical trials showcase
- A prospective trial of computer-aided detection (CAD) in the UK Breast Screening Programme (CADET II)
  Fiona Gilbert
  University of Aberdeen, UK
- Cetuximab in advanced non-small cell lung cancer: the FLEX Trial
  Robert Pirker
  Medical University of Vienna, Austria
- Mature data from Medical Research Council (MRC) randomised trials in 2466 patients with Stage 1 seminoma
  Ben Mead
  Southampton General Hospital, UK

19.00 – 21.00 Drinks Reception

19.00 – 21.00 Affymetrix Evening Symposium and Reception, featuring talks on “Integrated Approaches to Genomics”

20.00 – 22.30 Chairman’s Reception (by invitation)
# Programme at a glance  
**Tuesday**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 08.50</td>
<td>Educational workshops</td>
</tr>
<tr>
<td></td>
<td>• BOA Educational Workshop</td>
</tr>
<tr>
<td></td>
<td>• BACR Educational Workshop</td>
</tr>
</tbody>
</table>
| 09.00 – 09.40 | **Prostate cancer: a biologic approach to lethal disease**  
|          | **Howard Scher**                                   |
|          | Memorial Sloan Kettering Cancer Center, New York, USA |
| 09.40 – 10.20 | **Inflammation and cancer: organ-specific regulation of cancer development**  
|          | **Lisa Coussens**                                  |
|          | UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA |
| 10.20 – 11.00 | Refreshment Break and Exhibition Viewing          |
| 11.00 – 12.30 | **Symposia**                                      |
|          | • Imaging: from molecules to patients               |
|          | **Hosted by Kevin Brindle**                        |
|          | University of Cambridge, UK                        |
|          | • Novel therapies: from gene to drug                |
|          | **Hosted by Paul Workman**                         |
|          | The Institute of Cancer Research, Sutton, UK       |
|          | • The cost of cancer care                          |
|          | **Hosted by Mike Richards**                        |
|          | National Cancer Director, NHS, UK                  |
| 12.30 – 15.00 | Lunch, Poster Session 3 and Trade Exhibition       |
| 13.00 – 14.00 | **Commercial Workshop**                           |
|          | • Next generation sequencing: new frontiers in cancer genome biology – sponsored by Illumina |
| 14.00 – 15.00 | **Workshops**                                     |
|          | • Facilitating clinical-basic science interfaces   |
|          | • NCRN clinical research workshop                  |
|          | • How to write an effective grant proposal         |
|          | • Making effective poster presentations            |
15.15 – 17.30  **Parallel sessions**
- Breast cancer
- Cell death
- Drug discovery and medicinal chemistry
- Improving the effectiveness of multidisciplinary team working
- MicroRNAs in cancer
- Molecular imaging for cancer
- Research challenges for rare cancers
- Screening and estimation of prognosis
- Using information to improve cancer care
- Proffered Paper Highlights (Session 2)

17.30 – 18.00  Refreshment Break

18.00 – 18.40  **Tailoring adjuvant systemic therapy for breast cancer: dream or reality?**
Martine Piccart
Institut Jules Bordet, Brussels, Belgium

18.40 – 19.20  **Models of molecular diversity in breast cancer to guide marker guided therapy**
Joe Gray
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

19.30 – 23.00  Pfizer/BOA Excellence in Oncology Awards

20.00 – 20.30  Drinks Reception

20.30 – 02.00  Conference Dinner and Party
## Programme at a glance Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 11.15</td>
<td><strong>Parallel sessions</strong></td>
</tr>
<tr>
<td></td>
<td>- Cancer and older people</td>
</tr>
<tr>
<td></td>
<td>- Cancer vaccines</td>
</tr>
<tr>
<td></td>
<td>- Cell signalling</td>
</tr>
<tr>
<td></td>
<td>- Hepatocellular cancer</td>
</tr>
<tr>
<td></td>
<td>- Increasing public awareness of clinical trials</td>
</tr>
<tr>
<td></td>
<td>- Informatics</td>
</tr>
<tr>
<td></td>
<td>- Models of cancer</td>
</tr>
<tr>
<td></td>
<td>- Ovarian cancer</td>
</tr>
<tr>
<td></td>
<td>- Robotics and minimally invasive surgery</td>
</tr>
<tr>
<td></td>
<td>- Stem cells in cancer</td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>11.45 – 12.25</td>
<td><strong>Ras genes, Ras oncogenes and cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Mariano Barbacid</strong></td>
</tr>
<tr>
<td></td>
<td>Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain</td>
</tr>
<tr>
<td>12.25 – 12.35</td>
<td>Closing Comments</td>
</tr>
<tr>
<td></td>
<td><strong>Sir Kenneth Calman</strong></td>
</tr>
<tr>
<td></td>
<td>Chair of the National Cancer Research Institute</td>
</tr>
<tr>
<td>12.35 – 13.30</td>
<td>Lunch Boxes Available</td>
</tr>
</tbody>
</table>
Symposia in detail Monday

**Living beyond cancer**
Hosted by Jessica Corner and Jane Maher
Macmillan Cancer Support, UK
- **Jessica Corner and Jane Maher**
  Macmillan Cancer Support, UK
  Introduction
- **Peter Rose**
  University of Oxford, UK
  Care of long term adult cancer survivors in primary care
- **Karen Luker**
  University of Manchester, UK
  Perspectives on returning to work after treatment for cancer
- **Julia Rowland**
  National Cancer Institute, USA
  Survivorship research: informing life and care after cancer

**Targeting vascular biology**
Hosted by Tim Eisen
Hutchison/MRC Research Centre, Cambridge, UK
- **Tim Eisen**
  Hutchison/MRC Research Centre, Cambridge, UK
  Introduction
- **George Thomas**
  The Institute of Cancer Research, Sutton, UK
  Title to be confirmed
- **John Heymach**
  MD Anderson Cancer Centre, Houston, USA
  Rational design of combination regimens using antiangiogenic agents
- **Adrian Harris**
  Weatherall Institute of Molecular Medicine, University of Oxford, UK
  Angiogenesis inhibitors, current drugs and new targets

**The cell cycle in cancer**
Hosted by John Diffley
CR-UK London Research Institute, UK
- **John Diffley**
  CR-UK London Research Institute, UK
  Introduction
- **Kim Nasmyth**
  University of Oxford, UK
  The cohesin ring cycle: how cells first build and then break sister chromatid cohesion during mitosis and meiosis
- **Bruce A Edgar**
  Fred Hutchinson Cancer Research Centre, Washington, USA
  Developmental control of cell cycle exit in drosophila
- **John Diffley**
  CR-UK London Research Institute, UK
  DNA replication and cancer: lessons from budding yeast
Symposia in detail Tuesday

Imaging: from molecules to patients
Hosted by Kevin Brindle
University of Cambridge, UK
- **Kevin Brindle**
  University of Cambridge, UK
  Introduction
- **Kevin Brindle**
  University of Cambridge, UK
  Detecting tumour responses to treatment with magnetic resonance imaging
- **Uwe Haberkorn**
  University Hospital of Heidelberg, Germany
  Biotechnology in nuclear medicine
- **Vasilis Ntziachristos**
  Technische Universität München & Helmholtz Zentrum Munich Institute for Biological and Medical Imaging, Neuherberg, Germany
  Advancing biological discovery with *in-vivo* photonic imaging

Novel therapies: from gene to drug
Hosted by Paul Workman
The Institute of Cancer Research, Sutton, UK
- **Paul Workman**
  The Institute of Cancer Research, Sutton, UK
  Introduction
- **Paul Workman**
  The Institute of Cancer Research, Sutton, UK
  Inhibitors of the HSP90 chaperone pathway
- **Carlos Garcia-Echeverria**
  Novartis Institutes for Biomedical Research, Basel, Switzerland
  Identification and development of NVP-BEZ235 - a dual PI3K/mTOR inhibitor in Phase I clinical trials
- **Garth Powis**
  MD Anderson Cancer Center, Houston, USA
  Hypoxic stress signalling as a target for cancer drug development

The cost of cancer care
Hosted by Mike Richards
National Cancer Director, NHS, UK
- **Mike Richards**
  National Cancer Director, NHS, UK
  Introduction: the cost of cancer symposium
- **Andrew Dillon**
  National Institute for Health and Clinical Excellence, UK
  The contribution of NICE to effective cancer care
- **Richard Tiner**
  Association of the British Pharmaceutical Industry, London, UK
  The cost of cancer care from an industry perspective
- **Jessica Corner**
  Macmillan Cancer Support, UK
  The costs of cancer to patients and society
Parallel sessions in detail Monday

**Colorectal cancer**
Hosted by Tim Maughan
Cardiff University, UK
- **Tim Maughan**
  - Cardiff University, UK
  - Introduction
- **Richard Houlston**
  - The Institute of Cancer Research, Sutton, UK
  - Emerging architecture of colorectal cancer predisposition
- **Trevor Dale**
  - Cardiff University, UK
  - Targeting the Wnt signalling pathway
- **Sabine Tejpar**
  - University Hospital Gasthuisberg, Leuven, Belgium
  - Predicting response to epidermal growth factor receptor inhibitors in colorectal cancer
- **Howard McLeod**
  - Washington University, St Louis, USA
  - Pharmacogenetics in colorectal cancer therapy

Proffered paper presentation:
- **Richard Hubner**
  - The Institute of Cancer Research, Sutton, UK
  - Investigating prognostic and predictive influences of germline polymorphisms on colorectal adenoma recurrence

**Depression and assisted suicide in cancer patients**
Hosted by Julia Addington-Hall
University of Southampton, UK
- **Julia Addington-Hall**
  - University of Southampton, UK
  - Introduction
- **Jane Walker**
  - University of Edinburgh, UK
  - 'Better off dead': thoughts of death and suicide in cancer patients
- **Jesse Fann**
  - University of Washington, USA
  - Suicide rates in US cancer patients
- **Harvey Max Chochinov**
  - University of Manitoba and Manitoba Palliative Care Research Unit, Canada
  - The experiential landscape of terminal illness

Proffered paper presentations:
- **Louise Jones**
  - Marie Curie Palliative Care Research Unit, University College London, UK
  - Continuity of care in patients with cancer: development and evaluation of a complex intervention
- **Kate Jenkins**
  - Salisbury NHS Foundation Trust, UK
  - Implementing and evaluating a four tier model of psychological support. Results from a three year study
o **Eike Adams**  
Oxford Brookes University, UK  
A systematic review of the information needs of partners and family members of cancer patients

**Ensuring equality and diversity in trial recruitment**

Derek Stewart  
Consumer Liaison Group, UK

- **Derek Stewart**  
  Consumer Liaison Group, UK  
  **Introduction**

- **Janet Dunn**  
  Warwick Medical School, University of Warwick, UK  
  Improving ethnic data collection for cancer

- **Tariq White**  
  University of Leeds, UK  
  Equality and diversity-part of everyone’s business

- **Claire Foster**  
  University of Southampton, UK  
  Involvement of ethnic minorities in cancer research: experiences, barriers and recommendations

**Proffered paper presentations:**

- **Irene Tuffrey-Wijne**  
  St George’s Hospital, University of London, UK  
  The experiences of people with learning disabilities who have cancer: an ethnographic study

- **Aileen Timmons**  
  National Cancer Registry, Cork, Ireland  
  Financial impact of a cancer diagnosis for patients and their families: a qualitative study among oncology social workers and patients

**Genome stability in cancer**

Hosted by Steve Jackson  
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK

- **Steve Jackson**  
  Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK  
  **Introduction**

- **Graeme Smith**  
  KuDOS Pharmaceuticals Ltd, Cambridge, UK  
  DNA repair pathways as targets for therapeutics

- **Alan D'Andrea**  
  Dana-Farber Cancer Institute, Boston, USA  
  Targeting DNA repair pathways in cancer therapeutics

- **Thanos Halazonetis**  
  University of Geneva, Switzerland  
  An oncogene-induced DNA replication stress model for human cancer development
Proffered paper presentations:

- **Ricky A Sharma**
  University of Oxford, UK
  DNA polymerase beta modulates sensitivity and resistance of colon cancer cells to oxaliplatin via DNA damage repair

- **Anthony Chalmers**
  Brighton and Sussex Medical School, UK
  KU-0059436 plus radiation as first line therapy for glioblastoma multiforme: rationale and phase I clinical trial protocol

- **Celine Cano**
  Northern Institute for Cancer Research, Newcastle Upon Tyne, UK
  Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)

### Hormones and cancer
Hosted by Malcolm Parker
Imperial College London, UK

- **Malcolm Parker**
  Imperial College London, UK
  Introduction

- **Roland Schuele**
  Klinikum der Universitat Freiburg, Germany
  Androgen receptor function is regulated by histone demethylases: implication for prostate cancer

- **Donald McDonnell**
  Duke University Medical Centre, Durham, USA
  Validation of the estrogen related receptor as a therapeutic target in breast cancer

- **Arthur Zelent**
  Leukaemia Research Fund Centre, The Institute of Cancer Research, London, UK
  Deregulation of RARγ and RARγ-specific miRNAs in acute myeloid leukaemia

Proffered paper presentations:

- **Xenia Schmidt**
  Bute Medical School, University of St Andrews, UK
  Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells

- **Madryn Lake**
  Imperial College London, UK
  Non-invasive imaging of ER: coregulator interactions using luciferase fragment complementation

- **Martin K Thomsen**
  The Institute of Cancer Research, London, UK
  The role of Sox9 in prostate development and cancer
Mechanisms of resistance
Hosted by Robert Brown
Imperial College London, UK

- **Robert Brown**
  Imperial College London, UK
  Introduction

- **Tessa Holyoake**
  University of Glasgow, UK
  Characterisation and eradication of cancer stem cells in chronic myeloid leukaemia

- **Simak Ali**
  Imperial College London, UK
  Mechanisms of resistance to endocrine therapies in breast cancer

- **Frank Slack**
  Yale University, New Haven, USA
  MicroRNAs in development and cancer

Proffered paper presentations:

- **Charles Swanton**
  Cancer Research UK London Research Institute, UK
  Functional genomic annotation of microtubule stabiliser response defines chromosomal instability as a determinant of taxane sensitivity *in vivo*

- **Olivier E Pardo**
  Imperial College London, UK
  An FGFR inhibitor prevents chemoresistance *in vitro* and *in vivo*: a novel therapy for small cell lung cancer

- **Arvind Arya**
  University of Liverpool, UK
  The use of Nutlin-3 as a radiosensitiser in laryngeal carcinoma cells harbouring wild-type p53

Melanoma
Hosted by Xin Lu
Ludwig Institute for Cancer Research, Oxford, UK

- **Xin Lu**
  Ludwig Institute for Cancer Research, Oxford, UK
  Introduction

- **Colin Goding**
  Ludwig Institute for Cancer Research, Oxford, UK
  From stem cells to cancer: deciphering the Mitf code

- **Markus Frank**
  Brigham and Women's Hospital, Boston, USA
  Melanoma stem cells: implications for therapy

- **Vincenzo Cerundolo**
  University of Oxford, UK
  Harnessing NKT cells in cancer vaccination strategies

- **Elizabeth Patton**
  University of Edinburgh, UK
  Chemical-genetic approaches to identify novel compounds that sensitize melanocytes for cell death

- **Mark Middleton**
  University of Oxford, UK
  Defining who benefits from treatment for melanoma
Paediatrics
Hosted by Nazneen Rahman¹ and Sue Burchill²
¹The Institute of Cancer Research, Sutton, UK; ²Cancer Research UK Clinical Centre, St James’s University Hospital, Leeds, UK

- **Nazneen Rahman**
  - The Institute of Cancer Research, Sutton, UK
  - Introduction

- **John Maris**
  - The Children's Hospital of Philadelphia, USA
  - The genetic basis of human neuroblastoma

- **Heinrich Kovar**
  - Children’s Cancer Research Institute, Vienna, Austria
  - A NOTCH activation-dependent mechanism of tumour suppression involving p53 in Ewing’s sarcoma

- **Mel Greaves**
  - The Institute of Cancer Research, London, UK
  - Clonal evolution in childhood acute lymphoblastic leukaemia

Proffered paper presentations:

- **Qian An**
  - University of Southampton, UK
  - Variable breakpoints target PAX5 in patients with dicentric chromosomes; a model for the basis of unbalanced translocations in cancer

- **Richard Scott**
  - The Institute of Cancer Research, Sutton, UK
  - Detailed constitutional epigenetic and copy number analysis of the 11p15 growth regulatory region in Wilms tumour by MS-MLPA

- **Tim Forsheew**
  - Barts and The London School of Medicine and Dentistry, UK
  - Molecular genetic and epigenetic analysis of paediatric low-grade gliomas

Proffered paper highlights (session 1)
Hosted by Nic Jones¹ and Donna Johnstone²
¹Paterson Institute for Cancer Research, Manchester, UK; ²Manchester Cancer Research Centre, UK

- **Radoslaw Polanski**
  - University of Liverpool, UK
  - NME1 and NME2 regulate activities of p53 and MDM2

- **Frances Fuller-Pace**
  - University of Dundee, UK
  - The transcriptional coactivator p68 regulates expression of novel p53 isoforms that are critical for transcriptional activation by p53

- **Christoper Ricketts**
  - University of Birmingham School of Medicine, UK
  - Germline SDHB mutations and familial renal cell carcinoma

- **Wendy Cooper**
  - University of Birmingham, UK
  - The proapoptotic kinases MST1 and MST2 interact with RASSF2 translocating it from the nucleus to the cytoplasm
Aoife Shannon  
University of Manchester, UK  
The MEK1/2 inhibitor AZD6244 (ARRY-142886) increases the therapeutic benefits of radiotherapy and inhibits the tumour hypoxia response in a lung tumour xenograft model

Jonathan Tyrer  
University of Cambridge, UK  
Genetic susceptibility to ovarian cancer: results from the first stage of a genome-wide association study

Jo Morris  
King’s College London, UK  
DNA damage induces SUMO modification of BRCA1

Marissa V Powers  
The Institute of Cancer Research, Sutton, UK  
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumour-specific apoptosis

Understanding health behaviours relevant to cancer  
Hosted by Roger Wilson  
Consumer Liaison Group, UK

Roger Wilson  
Consumer Liaison Group, UK  
Introduction

Willem van Mechelen  
VU University Medical Center, Amsterdam, The Netherlands  
Physical activity interventions for people and places; self-responsibility or ‘the Nanny State’?

Jane Wardle  
University College London, UK  
New directions for behaviour change research in cancer prevention

Gerard Hastings  
Institute for Social Marketing and the Centre for Tobacco Control Research, University of Stirling and the Open University, UK  
Title to be confirmed

Proffered paper presentations:

Victoria Benson  
University of Oxford, UK  
Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort

Alan Casson  
University of Saskatchewan, Canada  
Physical activity, obesity and risk for esophageal adenocarcinoma

Maria Traka  
Institute of Food Research, Norwich, UK  
Consuming broccoli interacts with GSTM1 genotype to perturb oncogenic signalling pathways in the human prostate
Parallel sessions in detail Tuesday

**Breast cancer**
Hosted by Mitch Dowsett
The Royal Marsden Hospital, London, UK
  o **Mitch Dowsett**
    The Royal Marsden Hospital, London, UK
    Introduction
  o **Herve Bonnefoi**
    Hospitaux Universitaires de Geneve, Geneva, Switzerland
    Should we select specific chemotherapy regimens based on tumour molecular subtypes?
  o **Laura van t’Veer**
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Molecular profiling of early breast cancer guides treatment planning
  o **Andy Tutt**
    Guy's & St Thomas's NHS Foundation Trust, London, UK
    Triple negative breast cancer: diagnosis or dustbin

Proffered paper presentations:
  o **Mike Gonzalez**
    MRC Cancer Cell Unit, Cambridge, UK
    Geminin regulates DNA replication and predicts clinical outcome in breast cancer
  o **Louise Li**
    Northern Centre for Cancer Treatment, Newcastle, UK
    Integration of HER-2 result into breast multidisciplinary decision making: results of a UK audit
  o **Sarah Brown**
    University of Leeds, UK
    MR Imaging in breast cancer – results of the COMICE trial

**Cell death**
Hosted by Eyal Gottlieb
Beatson Institute for Cancer Research, Glasgow, UK
  o **Eyal Gottlieb**
    Beatson Institute for Cancer Research, Glasgow, UK
    Introduction
  o **Eileen White**
    Rutgers University, Piscataway, USA
    Role of autophagy in cancer progression and therapy
  o **Michael Hengartner**
    Institute of Molecular Biology, University of Zurich, Switzerland
    Regulation of DNA damage-induced apoptosis by the HIF pathway in the nematode *C. elegans*
  o **Xin Lu**
    Ludwig Institute for Cancer Research, Oxford, UK
    ASPP2 mediates senescence and inhibits autophagy and tumourgenicity induced by H-RasV12
Proffered paper presentations:

- **Afshan Ahmed**
  University College London, UK
  Regulation of cell death responses in hypoxia

- **Andrew Young**
  Cancer Research UK Cambridge Research Institute, UK
  Role for autophagy in the establishment of senescence

- **Dean Fennell**
  Queen’s University Belfast, Northern Ireland, UK
  The BH3 peptidomimetic obatoclax restores absent mitochondrial death signals in cisplatin resistant non-small cell lung cancer

**Drug discovery and medicinal chemistry**

Hosted by Roger Griffin
Newcastle University, UK

- **Roger Griffin**
  Newcastle University, UK
  Introduction

- **Sir Tom Blundell**
  University of Cambridge, UK
  Exploring chemical and biological space: new approaches to drug discovery in oncology

- **Martin Noble**
  University of Oxford, UK
  Structure-function and structure-inhibition relationships in the CDK family

- **Bob Jackson**
  Pharmacometrics Ltd, Cambridge, UK
  Identifying the next generation of anticancer drug targets

Proffered paper presentations:

- **Anna Watson**
  Northern Institute for Cancer Research, Newcastle upon Tyne, UK
  Isoindolinone inhibitors of the MDM2-p53 protein-protein interaction: structure-activity studies

- **Hakim Djeha**
  Antisoma Research Ltd, Welwyn Garden City, UK
  A novel small molecule inhibits cancer cell proliferation in vitro and in vivo via activation of the protein kinase AMPK

- **Esther Bridges**
  Lund University, Malmö, Sweden
  Role of PI3K signalling pathway in modulating hypoxia response in neuroblastoma

**Improving the effectiveness of multidisciplinary team working**

Hosted by Lesley Fallowfield
University of Sussex, Brighton, UK

- **Lesley Fallowfield**
  University of Sussex, Brighton, UK
  Introduction

- **Lesley Fallowfield**
  University of Sussex, Brighton, UK
  The multidisciplinary team in clinical trials: a Cancer Research UK training initiative
- Jane Blazeby
  University of Bristol, UK
  Optimising decision-making in multi-disciplinary teams
- Cath Taylor
  Adamson Centre for Mental Health, St Thomas' Hospital, UK
  Improving the working lives of UK colorectal cancer teams: an evaluation of the Pelican team-based training programme

Proffered paper presentations:
- Clarisa TP Choh
  United Bristol Healthcare Trust, UK
  The role of upper gastrointestinal multidisciplinary teams in recruiting patients into randomised controlled trials
- Liz Forbat
  Cancer Care Research Centre, University of Stirling, UK
  Using patient involvement and patient experience to drive service change: a case example from cancer care

MicroRNAs in cancer
Hosted by Eric Miska
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
- Eric Miska
  Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
  Introduction
- Richard Gregory
  Children's Hospital, Harvard University, USA
  Regulation of miRNA processing in embryonic stem cells and cancer
- Eric Miska
  Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
  MicroRNA regulatory networks
- Reuwen Agami
  Netherlands Cancer Institute, Amsterdam, The Netherlands
  Cancerous miRNAs and regulatory RNA binding proteins

Proffered paper presentations:
- Edoardo Missiaglia
  The Institute of Cancer Research, Sutton, UK
  MicroRNAs in childhood rhabdomyosarcoma
- Saiful Miah
  University of Sheffield, UK
  MicroRNA expression and profiling of bladder cancer
- Katja Seipel
  Cardiff University, Wales, UK
  RNA interference screen of the human Wnt signaling pathway

Molecular imaging for cancer
Hosted by Chris Nutting¹ and Frances Calman²
¹President of the British Oncological Association, UK; and ²Chairman of the Scientific Programme Committee, The Royal College of Radiologists, UK
- Chris Nutting
  President of the British Oncological Association (BOA), UK
  Introduction
• Mikael Pittet  
Harvard Medical School, Boston, USA  
Current methods of molecular imaging

• Susan Galbraith  
Bristol-Myers Squibb, Princeton, USA  
Molecular imaging in Phase 1 trials

• Ilja Frank Ciernik  
Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland  
Functional imaging applied to radiotherapy

Proffered paper presentations:

• Andrew Gaya  
Mount Vernon Hospital, Northwood, Middlesex, UK  
Inter-lesional variability of DCE-MRI response and changes in cardiac output following infusion of the vascular disruptive agent Combretastatin-A4-Phosphate (CA4P)

• Martin Christlieb  
University of Oxford, UK  
Developing new PET tracers and studying them with new techniques

• Christophe Badie  
Health Protection Agency, Chilton, UK  
Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response

Proffered paper highlights (session 2)  
Hosted by Stan Kaye
Chair of the Programme Planning Committee, and Institute of Cancer Research and Royal Marsden Hospital, UK

• Chris Parker  
The Institute of Cancer Research, Sutton, UK  
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer with respect to the outcome of radical treatment

• Michael Brada  
The Institute of Cancer Research, Sutton, UK  
A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944)

• Usha Menon  
University College London EGA Institute for Women’s Health, UK  
Outcome of the prevalence screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

• Astri Syse  
Cancer Registry of Norway, Oslo, Norway  
A population-based study of marriage and divorce in survivors of adult cancers in Norway

• Laura Gay  
University of Cambridge Pathology Department, UK  
Effect of diet on APC mutation spectra in sporadic colorectal tumours from the EPIC-Norfolk Study

• Henry Kitchener  
University of Manchester, UK  
HPV testing in combination with liquid-based cytology in primary cervical screening: a randomised trial
Research challenges for rare cancers
Hosted by Roger Wilson
Consumer Liaison Group, UK
- **Roger Wilson**
  Consumer Liaison Group, UK
  Introduction
- **Penny Wilson-Webb**
  Rarer Cancers Forum, UK
  The patient wants to see…
- **Peter Littlejohns**
  National Institute for Health and Clinical Excellence (NICE), UK
  The regulator’s viewpoint
- **Jean-Yves Blay**
  Université Claude Berard, Lyon, France
  Collaboration is one route
- **Lucinda Billingham**
  Cancer Research UK Clinical Trials Unit, University of Birmingham, UK
  Alternative approaches to trial design

Screening and estimation of prognosis
Hosted by Bob Steele
University of Dundee, UK
- **Bob Steele**
  University of Dundee, UK
  Introduction
- **Phil Quirke**
  University of Leeds, UK
  Progress in the estimation of prognosis in cancer
- **Lawrence von Karsa**
  International Agency for Research on Cancer, Lyon, France
  Cancer screening in Europe
- **Julietta Patnick**
  NHS Cancer Screening Programmes, Sheffield, UK
  Cancer Screening in the UK

Proffered paper presentations:
- **Fahd Al-Mulla**
  Kuwait University, Kuwait
  Raf kinase inhibitor protein (RKIP) expression in colorectal cancer is associated with metastatic recurrence and reduced overall survival: from discovery to function
- **Judith Murphy**
  National Cancer Registry Ireland, Cork, Ireland
A focus group study in Ireland of women’s views, attitudes and knowledge of cervical screening and Human Papillomavirus (HPV)

- Elizabeth Grunfeld
  King’s College London, UK
  Predictors of return to work in cancer survivors

**Using information to improve cancer care**

Hosted by David Forman

National Cancer Intelligence Network / Centre for Epidemiology and Biostatistics, University of Leeds, UK

- David Forman
  National Cancer Intelligence Network / Centre for Epidemiology and Biostatistics, University of Leeds, UK
  Introduction
- Anna Gavin
  Queen's University Belfast, Northern Ireland, UK
  Using registry data to monitor cancer strategy implementation
- Elizabeth Davies
  King’s College London, UK
  Investigating cancer incidence, stage, treatment, and survival for different ethnic groups in South East England
- Michel Coleman
  London School of Hygiene and Tropical Medicine, UK
  Relevance of international survival comparisons for the UK

**Proffered paper presentations:**

- Ken Lloyd
  Oxford Cancer Intelligence Unit, UK
  Using information to improve cancer care at network level
- Diana Bailey
  South West Public Health Observatory, Salisbury, UK
  Do patients with oesophageo-gastric cancer have a longer referral time and worse outcome if aged under 55? A prospective multicentre study
- Ranjeet Jeevan
  Royal College of Surgeons of England, London, UK
  Variation in the provision of immediate breast reconstruction in England
Parallel sessions in detail Wednesday

Cancer and older people
Hosted by Amanda Ramirez
King’s College London, UK
- Amanda Ramirez
  King’s College London, UK
  Introduction
- Katrina Lavelle
  University of Manchester, UK
  Non standard management of older women with breast cancer in the UK
- Riccardo Audisio
  Whiston Hospital, Prescot, UK
  Surgical mistreatment of older cancer patients
- Martine Extermann
  Moffitt Cancer Center, University of South Florida, USA
  Anticancer treatment: what do older patients want?

Proffered paper presentations:
- Caroline Burgess
  Institute of Psychiatry, Kings College London, UK
  Promoting early presentation of breast cancer: implementation and evaluation of a training programme for radiographers to deliver a psycho-educational intervention
- Judith Mills
  The Institute of Cancer Research, Sutton, UK
  How much do age, clinical and psychological factors contribute to fatigue following radiotherapy for early breast cancer? Evidence from the START Trials (UK Standardisation of Breast Radiotherapy)
- Lorna Fern
  University College Hospitals, London, UK
  Addressing delayed cancer diagnosis in primary care: Patterns of attendance and symptoms of teenagers and young adults seen in three general practices during one year

Cancer vaccines
Hosted by Peter Johnson
University of Southampton, UK
- Peter Johnson
  University of Southampton, UK
  Introduction
- Robert Vonderheide
  University of Pennsylvania, Philadelphia, USA
  Telomerase-based immunotherapy of cancer
- Christian Ottensmeier
  University of Southampton, UK
  DNA fusion gene vaccination, delivered with or without in vivo electroporation - a potent and safe strategy for inducing anti-tumour immune responses in prostate cancer
- **Frédéric Triebel**  
  Immutep SA, Paris, France  
  IMP321 and weekly paclitaxel as first-line chemo-immunotherapy in metastatic breast cancer (MBC)

**Proffered paper presentations:**
- **Munitta Muthana**  
  University of Sheffield, UK  
  Use of nanomagnets to enhance monocyte delivery of gene therapy to tumours
- **Mark Cobbold**  
  University of Birmingham, UK  
  Immunological targeting of the cancer phosphoproteome
- **Michael Salako**  
  The Institute of Cancer and CR-UK Clinical Centre, Barts and The London School of Medicine and Dentistry, London, UK  
  Targeting inflammatory cytokines using adenoviruses- gene delivery of biological therapies in ovarian cancer

**Cell signalling**  
Hosted by Richard Marais  
The Institute of Cancer Research, London, UK
- **Richard Marais**  
  The Institute of Cancer Research, London, UK  
  Introduction
- **Boris Bastian**  
  University of California, San Francisco, USA  
  Frequent somatic mutations of GNAQ in uveal melanoma and intradermal melanocytic proliferations
- **Margaret Frame**  
  University of Edinburgh, UK  
  Targeting invasion and metastasis
- **John Blenis**  
  Harvard Medical School, Boston, USA  
  ERK-MAP kinase signalling: biological context, cellular location, signal strength and duration dictate cell fate

**Proffered paper presentations:**
- **Stephanie Kermorgant**  
  Barts & The London School of Medicine, London, UK  
  C-Met oncogenic mutants sustain signals in the endosome and are protected against downregulation
- **Laura Harrington**  
  Weatherall Institute of Molecular Medicine, University of Oxford, UK  
  Cross talk between the VEGF and Notch signalling pathways in endothelial cells
- **Janine Erler**  
  The Institute of Cancer Research, London, UK  
  Lysyl oxidase secreted by hypoxic tumour cells is critical for pre-metastatic niche formation
Hepatocellular cancer  
Hosted by Philip Johnson  
University of Birmingham, UK

- Philip Johnson  
  University of Birmingham, UK  
  Introduction
- Nathalie Wong  
  Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China  
  Molecular biology of hepatocellular carcinoma
- Riccardo Lencioni  
  University of Pisa, Rome, Italy  
  The role of ablative therapies in hepatocellular carcinoma
- Philip Johnson  
  University of Birmingham, UK  
  New systemic approaches and trial design
- Tim Meyer  
  Royal Free Hospital, London, UK  
  Current and future trials in hepatocellular cancer

Proffered paper presentations:
- Gary Beale  
  Newcastle University, UK  
  Inhibition of ATM mediated DNA repair potentiates the cytotoxicity of DNA damaging ionising radiation in HCC cells

Increasing public awareness of clinical trials  
Hosted by Hilary Blackburn and Joanna Eley  
National Cancer Research Institute, London, UK

- Hilary Blackburn and Joanna Eley  
  National Cancer Research Institute, London, UK  
  Introduction
- Jim Elliott  
  Macmillan Cancer Support, UK  
  Increasing public awareness in research from the perspective of a cancer care and support charity
- Louise Locock  
  DIPEx, University of Oxford, UK  
  Personal experiences of clinical trials – a new website resource
- Barbara Moore  
  Wales Cancer Trials Network, Cardiff, UK  
  Research nurse perspective of increasing public awareness of clinical trials

Informatics  
Hosted by Sir Mike Brady  
University of Oxford, UK

- Sir Mike Brady  
  University of Oxford, UK  
  Introduction
- Nicholas Ayache  
  INRIA (French Research Institute of Computer Science and Automatic Control), Sophia-Antipolis, France  
  Personalizing in silico models of tumours with in vivo medical images
John Overington
BioFocus DPI, London, UK
Informatics support for the discovery of new therapeutics

John Quackenbush
Dana-Farber Cancer Institute and the Harvard School of Public Health, Boston, USA
Information integration approaches to genomic data analysis

Proffered paper presentations:

- Speaker to be confirmed
- Philip Roy Quinlan
  University of Dundee, UK
  INSPIRE: An integrated web based informatics infrastructure for automated analysis of laboratory and clinical data
- Eva Morris
  University of Leeds, UK
  A national perspective on the surgical management and outcomes of colorectal cancer liver metastases

Models of cancer
Hosted by Inke Nathke
University of Dundee, UK

- Inke Nathke
  University of Dundee, UK
  Introduction
- Sir David Lane
  University of Dundee, UK
  Studying the p53 pathway in Zebrafish
- Caroline Hill
  CR-UK London Research Institute, UK
  Using Xenopus laevis as a model system to understand transforming growth factor β signalling mechanisms and function
- Alan Clarke
  Cardiff University, UK
  Investigating the link between Intestinal stem cells and neoplasia

Proffered paper presentations:

- Dhamayanthi Pugazhendhi
  University of Sheffield, UK
  Modulation of human JAK/STAT pathway signalling by functionally conserved regulators and their potential role in myeloid leukemia
- Rachel Brough
  The Institute of Cancer Research, London, UK
  Using the Drosophila protein to further our understanding of BRCA2
- Antonio Saha
  The Institute Of Cancer, CR-UK Clinical Centre, Barts and the London School Of Medicine and Dentistry, Queen Mary University of London, UK
  Systematic optimisation of in vivo imaging of αvβ6 in cancer
**Ovarian cancer**
Hosted by James Brenton
CR-UK Cambridge Research Institute, UK
- **James Brenton**
  CR-UK Cambridge Research Institute, UK
  Introduction
- **David Huntsman**
  Vancouver Coastal Health Research Institute, Canada
  Ovarian carcinoma subtypes are different diseases: implications for clinical and translational research
- **Iain McNeish**
  Barts and the London School of Medicine, UK
  Targeting cell cycle abnormalities in ovarian cancer using oncolytic adenoviruses
- **Elisabeth de Vries**
  University of Groningen, The Netherlands
  How to use new pathways to circumvent platinum resistance?

**Proffered paper presentations:**
- **Craig Carden**
  The Institute Cancer Research, Sutton, UK
  A Phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC)
- **Roshan Agarwal**
  Imperial College London, UK
  Alpha folate receptor (FOLR1) amplification and role in tumour growth independent of folate transport in ovarian cancer (EOC)
- **Quang-De Nguyen**
  Imperial College London, UK
  *In vitro and in vivo* evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer

**Robotics and minimally invasive surgery**
Hosted by David Neal
CR-UK Cambridge Research Institute, UK
- **David Neal**
  CR-UK Cambridge Research Institute, UK
  Introduction
- **Robin Kennedy**
  St Mark's Hospital, Harrow, UK
  Transforming outcomes of colorectal surgery in the laparoscopic era
- **John Primrose**
  Southampton General Hospital, UK
  Enabling minimally invasive liver surgery: case for a multidiscipline approach
- **Ash Tewari**
  New York Presbyterian Hospital, Weill Cornell Medical Centre, USA
  Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy
Proffered paper presentations:

- **Dongbin Chen**
  Imperial College London, UK
  Development of a stereo image guidance system to assist robotic surgery of prostate cancer using augmented reality

- **Ros Eeles**
  The Institute of Cancer Research, Sutton, UK
  Identification of multiple novel prostate cancer predisposition loci

- **Dmitry Pshezhetskiy**
  Imperial College London, UK
  The SK1/S1P pathway as a potential diagnostic/prognostic marker in prostate cancer

- **Jeremy Clark**
  The Institute of Cancer Research, Sutton, UK
  Incidence, diversity and clinical relevance of ETV1 translocations in human prostate cancer

**Stem cells in cancer**

Hosted by Phil Jones
Hutchison-MRC Research Centre, Cambridge, UK

- **Phil Jones**
  Hutchison-MRC Research Centre, Cambridge, UK
  Introduction

- **Michael Clarke**
  Stanford Comprehensive Cancer Centre, USA
  What can we learn about self renewal and cancer therapy from the prospective isolation of cancer stem cells?

- **Christopher Heeschen**
  Ludwig-Maximilians-University, Munich, Germany
  Stem cells in pancreatic cancer

- **Tariq Enver**
  University of Oxford, UK
  Molecular regulation of normal and leukaemic human haemataopoietic stem cells

Proffered paper presentations:

- **Mays Jawad**
  University of Nottingham, UK
  *In vitro* chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia

- **Hidekazu Yamamoto**
  University College London, UK
  Characterisation of prostate stem-like cells from phosphatase and tensin homolog (PTEN) deficient mice

- **Osama Al-Assar**
  University of Oxford, UK
  Cancer stem cells are not more radioresistant than non-stem cells in cell lines from different origins with the exception of the MDA MB231 breast cancer cell line
Workshops in detail Sunday

Metabolism and signalling in cancer: the Cancer Recognised Research Group in Northern Ireland (CRRG) workshop
12.30 – 14.45

- **John Blenis**
  Harvard Medical School, Boston, USA
  mTOR signaling, metabolism and cell growth

- **Edwina Dobbin, Ciaren Graham, Robin Freeburn and Helen Wheadon**
  Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
  Regulated expression of the leukaemic oncogene Tel/PDGFR beta in embryonic stem cells identifies the key signalling pathways involved in its pathogenesis

- **VM Hodges, Z Shi, E Dunlop, MJ Percy, MK El-Tanani and TRJ Lappin**
  Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK
  The role of the erythropoietin receptor in tumourigenesis

- **S van Schaeybroeck, JN Kyula, C Holohan, J Doherty, S Moulik, DB Longley and Patrick G Johnston**
  Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK
  Src and ADAM-17 mediated shedding of TGF-α is an acute mechanism of resistance to chemotherapy

- **Suzanne McFarlane¹, Ashleigh McClatchey¹, Tony O’Grady², Gillian O’Hurley², Patrick G Johnston¹, Elaine Kay² and David JJ Waugh¹**
  ¹Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK; ²Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
  CD44 initiates integrin-promoted cortactin and paxillin signaling to promote adhesion of metastatic breast and prostate cancer cells to bone marrow endothelium
Workshops in detail Monday

BOA educational workshop – ‘Meet the professor’
08.00 – 08.50
- Robert Coleman
  Weston Park Hospital Sheffield, UK
  Maintenance of bone health in cancer patients - a new priority for oncology

BACR educational workshop – Tissue microarrays and image analysis
08.00 – 08.50
Hosted by Liam Gallagher¹ and Elaine Kay²
¹University College Dublin, Ireland; ²Beaumont Hospital, Dublin, Ireland
- Donal Brennan
  University College Dublin, Ireland

Commercial workshop - K-RAS status in colorectal cancer: tailoring treatment to your patient
13.00 – 14.00
Hosted by Timothy Maughan
Velindre Hospital, Cardiff, Wales
- Sabine Tejpar
  University Hospital Gasthuisberg, Leuven, Belgium
  Why is K-RAS status important?
- Timothy Maughan
  Velindre Hospital, Cardiff, Wales
  Impact of K-RAS status on outcome to treatment
- Graeme Poston
  University Hospital Aintree, Liverpool, UK
  Patients with liver-only metastases: the potential for "cure"
- Rachel Butler
  All Wales Molecular Genetics Laboratory, Cardiff and Vale NHS Trust, Wales
  K-RAS testing in practice

Alternative and innovative designs of Phase I/II trials
14.00 – 15.00
Hosted by Patrick Johnston
Velindre Hospital, Cardiff, Wales
- Johann De Bono
  The Institute of Cancer Research, London, UK
  The academic perspective
- Andrew Hughes
  AstraZeneca Pharmaceuticals, Cheshire, UK
  The industrial view
How to publish and disseminate your results
14.00 – 15.00
Hosted by Adrian Harris
British Journal of Cancer, UK
  o Stella Hurtley
    Science Magazine, Cambridge, UK
    An editor’s perspective
  o Tony Kouzarides
    Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
    An author’s perspective
  o Steve Palmer
    Cancer Research UK, London, UK
    Working with the media

Leadership in scientific research
14.00 – 15.00
Hosted by Sarah Burns
Cancer Research UK, London, UK
  o Lesley Yellowlees
    University of Edinburgh, UK

NCRI data-sharing debate
14.00 – 15.00
Hosted by Richard Begent
University College London, UK
  o Peter Dukes
    Medical Research Council (MRC) Research Career Awards, Research Management Group, London, UK
  o Tim French
    Discovery Medicine, AstraZeneca, Macclesfield, UK
  o Matt Cockerill
    BioMed Central, London, UK
  o Sylvia Nagl
    University College London, UK
  o Kevin Johnson
    PanGenetics, Cambridge, UK
Workshops in detail  
	Tuesday

**BOA educational workshop – ‘Meet the professor’**
08.00 – 08.50
- **Kevin Harrington**
  The Institute of Cancer Research, London, UK
  Interfaces between classical and molecular radiobiology

**BACR educational workshop**
08.00 – 08.50
Hosted by Val Brunton
University of Edinburgh, UK
- **Kurt Anderson**
  Beatson Institute for Cancer Research, Glasgow, UK

**Commercial workshop - Next generation sequencing - New frontiers in cancer genome biology**
13.00 – 14.00
Details to be announced

**Facilitating clinical-basic science interfaces**
14.00 – 15.00
Hosted by Inke Nathke
University of Dundee, UK
- **Lisa Cotterill**
  National Co-ordinating Centre for Research Capacity Development, Leeds, UK
- **Alastair Thompson**
  University of Dundee, UK
- **Tim Illidge**
  University of Manchester, UK

**NCRN clinical research workshop**
14.00 – 15.00
Hosted by David Cameron
National Cancer Research Network and Western General Hospital, University of Edinburgh, UK

**How to write an effective grant proposal**
14.00 – 15.00
Hosted by Simon Vincent
Cancer Research UK, London, UK
- **Ian Hart**
  Chair of the Science Funding Committee, Cancer Research UK, London, UK
- **Iain McNeish**
  MRC Senior Clinical Fellow, Barts and the London School of Medicine, UK

**Making effective poster presentations**
14.00 – 15.00
Hosted by Pete Moore
ThinkWrite Training, Bristol, UK